Document is current
Any future updates will be listed below
-
Authors
Vollert, Jan https://orcid.org/0000-0003-0733-5201
Macleod, Malcolm https://orcid.org/0000-0001-9187-9839
Dirnagl, Ulrich https://orcid.org/0000-0003-0755-6119
Kas, Martien J. https://orcid.org/0000-0002-4471-8618
Michel, Martin C.
Potschka, Heidrun https://orcid.org/0000-0003-1506-0252
Riedel, Gernot
Wever, Kimberley E. https://orcid.org/0000-0003-3635-3660
Würbel, Hanno https://orcid.org/0000-0002-2934-3010
Steckler, Thomas
,
Rice, Andrew S. C.
-
Funding
Funding for this research was provided by:
Innovative Medicines Initiative (777364, 777364, 777364, 777364, 777364, 777364, 777364, 777364, 777364, 777364, 777364)
- License Information
-
More Information
Article History
First Online: 5 September 2022
Competing interests
: J.V. has received consulting fees from Casquar, Embody Orthopaedics and Vertex Pharmaceuticals. M.C.M. has received honorary and/or travel support in relationship to being a consultant and/or lecturer for the following pharmaceutical companies: Apogepha, Astellas, Boehringer Ingelheim, Dr. Willmar Schwabe, GSK and Sanofi-Aventis. H.P. has received funding for consulting, talks and research collaborations from Eisai, Zogenix, Bayer, Elanco, Roche, Exeed Epidarex, Lario, Angelini, Jazz Pharmaceuticals, Galapagos and MSD. A.S.C.R. declares remunerated consultancy work for Imperial College Consultants in last 24 months including for Confo, Vertex, Novartis, CombiGene, Orion and Shanghai SIMR Biotech.
